As the precision medicine industry witnesses exciting Drug-Dx approvals being driven by major advancements in biomarker development, the 12th Clinical Biomarker & CDx Summit Europe returns in 2022 to set the stage for key learnings with exclusive data to optimize your drug development programs with the most cutting-edge tools and techniques from start to finish.

The second day will address Drug-Dx Co-Development & Commercialisation Planning for Maximised Access.

Come and join us on our interactive session:

The session will start with a 30-45 presentation followed by a mini-workshop and Q&A discussion.